|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.73 CHF | +0.27% |
|
+4.47% | +17.34% |
| 06:51am | Novartis Says Chronic Skin Condition Drug Shows Positive Results in Trial | DJ |
| 06:47am | Novartis Reports Positive Results from Phase 3 Trial of Chronic Inducible Urticaria Oral Drug | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 56.67B | 24.64% | 38.62% | 38.4% | 16.33% | 1.02x | ||
| 65.18B | 31.67% | 41.84% | 103.86% | 22.92% | 0.95x | ||
| 94.19B | 28.46% | 32.23% | 34.62% | 14.26% | 0.73x | ||
| 56.33B | 7.59% | 41.43% | 263.08% | 13.34% | 2.56x | ||
| 77.58B | 20.94% | 35.49% | 47.65% | 15.43% | 0.66x | ||
| 54.07B | 13.01% | 31.31% | 32.11% | 12.51% | 1.47x | ||
| 64.17B | 26.68% | 36.46% | 46.35% | 17.38% | 0.86x | ||
| 48.59B | 33.14% | 41.3% | 60.7% | 20.31% | 0.69x | ||
| 36.75B | 20.98% | 44.09% | 162.88% | 12.98% | 2.13x | ||
| 28.75B | 1.67% | 29.63% | 27.6% | 9.57% | 1.48x | ||
| 63.63B | 12.62% | 34.24% | 19.99% | 8.05% | 1.52x | ||
| 12B | 32.94% | 43.85% | 27.07% | 16.41% | -1.18x | ||
| 48.19B | 14.64% | 30.37% | 72.08% | 7.72% | 1.83x | ||
| 39.28B | 8.21% | 29.16% | 48.09% | 10.97% | 1.22x | ||
| 42.53B | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
| 7.45B | 33.09% | 46.3% | 22% | 18.71% | -1.74x | ||
| 30.6B | 2.36% | 7.48% | 1.5% | 1.19% | 3.6x | ||
| 3.83B | 22.64% | 26.77% | 14.73% | 13.49% | -2.98x | ||
| 48.25B | -5.48% | 11.66% | 15.32% | -2.25% | 3.2x | ||
| 14.06B | 12.84% | 22.26% | 8.8% | 4.22% | 2.82x | ||
| Average | 44.61B | 17.83% | 32.61% | 52.93% | 11.9% | 1.08x | |
| Weighted average by Cap. | 58.14B | 21.67% | 36.26% | 74.31% | 15.19% | 1.10x |
- Stock Market
- Equities
- NOVN Stock
- Sector Novartis AG
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















